title: Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
abstract: Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers are very productive. The review on Drugs interacting with Enzymes was accepted in August 2012. However, this field is very dynamic. New potential targets for the treatment of Alzheimer's disease were identified. This update describes drugs interacting with 60 enzymes versus 43 enzymes in the first paper. Some compounds progressed in their development, while many others were discontinued. The present review covers the evolution of research in this field through April 2014.
authors.affiliation: AC Immune SA, EPFL, Lausanne, Switzerland.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Froestl
authors.affiliation: AC Immune SA, EPFL, Lausanne, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Muhs
authors.affiliation: AC Immune SA, EPFL, Lausanne, Switzerland.
authors.forename: Andrea
authors.initials: A
authors.lastname: Pfeifer
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D058990:Molecular Targeted Therapy; D018697:Nootropic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
chemical_list: D018697:Nootropic Agents
keywords: Alzheimer's disease; cognitive enhancers; donepezil; enzymes; galantamine; memory; rivastigmine